The C609T variant of NQO1 is associated with carotid artery plaques in patients with type 2 diabetes
Section snippets
Subjects
We have replicated a genetic analysis in two independent sample sets of patients with type 2 diabetes. The Seoul set and the Koyang set consisted of 601 patients from Severance Hospital Diabetes Center from September 2005 to December 2007 and 233 patients from Myongji Hospital from April 2003 to January 2007, respectively. Type 2 diabetes was defined according to the 1997 American Diabetes Association diagnostic criteria [9]. Patients with type 1 diabetes mellitus, a history of cancer,
Subject characteristics
The allele frequencies and genotype distribution are shown in Table 1. The proportion of subjects with the TT genotype was similar in the Seoul and Koyang sets (18.6% and 18.5%, respectively). The genotype distribution in both sets did not deviate significantly from the Hardy–Weinberg equilibrium (χ2 = 0.010, p = 0.937; χ2 = 0.498, p = 0.480, respectively). The clinical and biochemical characteristics of the subjects according to the NQO1 genotype are shown in Table 2. There was no significant
Discussion
The major finding of the present study is that the NQO1 C609T polymorphism is associated with carotid atherosclerosis in patients with T2DM. To our knowledge, this report is the first to show a significant association between NQO1 polymorphism and carotid artery plaques.
There is growing evidence that excessive, and highly reactive free radicals, largely due to hyperglycemia, cause oxidative stress, which further exacerbates the development and progression of diabetic complications.
Acknowledgments
This work was supported by a grant from the Faculty Research Grant of Yonsei University College of Medicine (6-2008-0259), Department of Internal Medicine (7-2008-0418), and a grant from Kim Myung Sun Memorial Foundation (2008).
References (30)
- et al.
NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms
Chem. Biol. Interact.
(2000) - et al.
DT-diaphorase and cancer chemotherapy
Biochem. Pharmacol.
(1992) - et al.
Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism
J. Biol. Chem.
(2003) - et al.
Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes
Diabetes Res. Clin. Pract.
(2005) - et al.
Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus
Metabolism
(2006) - et al.
Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity
Kidney Int.
(2004) - et al.
Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix–loop–helix transcription factors
Mutat. Res.
(2004) - et al.
Polymorphisms in the angiotensinogen gene are associated with carotid intimal-medial thickening in females from a community-based population
Atherosclerosis
(2001) The pathogenesis of atherosclerosis
Clin. Chim. Acta
(1996)- et al.
Adiponectin gene polymorphism 45T>G is associated with carotid artery plaques in patients with type 2 diabetes mellitus
Metabolism
(2008)
The pathobiology of diabetic complications: a unifying mechanism
Diabetes
The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger
Cardiovasc. Toxicol.
NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger
Mol. Pharmacol.
Flow, NO, and atherogenesis
Proc. Natl. Acad. Sci. USA
Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1
Pharmacogenetics
Cited by (23)
NADPH-quinone oxidoreductase-1 mediates Benzo-[a]-pyrene-1,6-quinone-induced cytotoxicity and reactive oxygen species production in human EA.hy926 endothelial cells
2020, Toxicology and Applied PharmacologyCitation Excerpt :In recent years, awareness about the protective effects of NQO1 has risen the possibility of using NQO1 as a possible therapy to slow down lipoprotein oxidation and prevent atherosclerosis. A study conducted on 834 type 2 diabetic patients showed that patients with NQO1*2 polymorphism had a higher occurrence of plaques in the carotid artery (Han et al., 2009). In another study, patients with NQO1*2 showed higher rates of inflammation after bypass surgery compared to patients without the polymorphism (Isbir et al., 2008).
Biased activity of soluble guanylyl cyclase: the Janus face of thymoquinone
2017, Acta Pharmaceutica Sinica BCitation Excerpt :Quinones are substrates of NADPH:quinone oxidoreductase (NQO-1), an enzyme expressed abundantly in the vascular wall both at the endothelial35 and at the smooth muscle36 levels. The enzyme, by detoxifying endogenous and xenobiotic quinones and their derivatives, prevents the participation of these substances in redox cycling, hence playing an important role in the defense against oxidative stress37–39. NQO-1 metabolizes thymoquinone, likely because of its structural resemblance to ubiquinone, the natural electron carrier in mitochondria40.
The genetics of vascular complications in diabetes mellitus
2010, Cardiology ClinicsForced Hepatic Expression of NRF2 or NQO1 Impedes Hepatocyte Lipid Accumulation in a Lipodystrophy Mouse Model
2023, International Journal of Molecular SciencesGenetic Polymorphism of NQO1 Influences Susceptibility to Coronary Heart Disease in a Chinese Population: A Cross-Sectional Study and Meta-Anaylsis
2023, Pharmacogenomics and Personalized Medicine
- 1
These authors contributed equally to this work.